SPRYCEL 20 mg film-coated tablets
Sponsors
Oslo University Hospital HF, Instituto De Investigacion En Ciencias De La Salud Germans Trias I Pujol, Masarykova Univerzita, Region Uppsala, Centre Hospitalier Universitaire De Poitiers
Conditions
Chronic Myeloid LeukemiaChronic myeloid leukemiaColorectal cancerHuman immunodeficiency viruschronic myeloid leukemia
Phase 2
An open-label single arm interventional phase 2 study to investigate outcome of individualized treatment based on pharmacogenomic profiling and ex vivo drug sensitivity testing of patient-derived organoids in patients with metastatic colorectal cancer
RecruitingCTIS2023-510092-62-00
Start: 2022-09-27Target: 45Updated: 2025-06-26
Safety and Impact of Dasatinib on Viral Persistence and Inflammation in People with HIV under Antiretroviral Treatment
Active, not recruitingCTIS2024-513714-36-01
Start: 2024-06-28Target: 60Updated: 2024-06-28
A Prospective Phase II Clinical Trial Evaluating the Efficacy and the Safety of Tyrosine Kinase Inhibitors Withdrawal After a Previous Two-step Dose Reduction in Patients With Chronic Myeloid Leukemia in Deep Molecular Remission
Active, not recruitingCTIS2024-514592-17-00
Start: 2020-06-16Target: 221Updated: 2025-11-06
Persistence of major molecular remission in chronic myeloid leukemia after a second stop of TKI treatment in patients who failed an initial stop attempt: a multicenter prospective trial. DASTOP2 TRIAL
RecruitingCTIS2024-515409-25-00
Start: 2018-01-11Target: 32Updated: 2025-03-03